VEMERIX Maps the Skin-Adhesive Supply Chain: 36 FDA Clearances, 14 Holders, and a Checklist to Verify Any Brand

Register analysis traces 97 US device listings from 20 labelers, and 239 China UDI records resolving to just 32 registrations — concentration that makes documents, not brand names, the basis for bulk sourcing

WEIHAI, China, Oct. 29, 2026 /PRNewswire/ -- VEMERIX, the international medical device brand of Weihai Medison Medical Equipment Co., Ltd., today released a documentation checklist for buyers sourcing medical cyanoacrylate adhesives in bulk, drawn from its September 2026 cyanoacrylate supplier-landscape report. The report's central finding: one chemistry label covers products with different intended uses, regulatory classes and manufacturers — so identifying a supplier runs through documents, not brand names.

In the US record, 36 FDA 510(k) clearances under product code MPN (topical tissue adhesives, December 2008 to September 2025) belong to just 14 applicant groups, with four companies holding 23 of the 36. The FDA's GUDID device listings show 97 MPN records from 20 labelers, and nine labelers without a clearance of their own account for 44 of those records (45%) — lawful private-label and relabeling arrangements through which much of this category reaches the market. The practical consequence: identifying the manufacturer behind a brand is a routine document exercise. In the EU database, forty-four topical records come from just six manufacturers, led by China (17 records) and the US (15) as registered origin countries.

Classification follows the claim, not the chemistry. China's catalogue places skin adhesives at Class III (code 02-13-09) while liquid dressings for non-chronic wounds sit at Class II (14-10-08) — in indication terms, the line runs between surgical closure and suture replacement (Class III) and superficial, assistive wound care (Class II). Its UDI database resolves 239 adhesive records to only 32 registrations. A skin-closure product cannot inherit another product's vascular or internal-surgical claim simply because both are cyanoacrylates — and "Class II" means a different thing in each market.

The checklist turns those findings into a first-contact document request:

• The exact product name and model of the adhesive to be supplied
• The legal manufacturer identified on the product labeling
• For a relabeled product, the clearance or registration holder standing behind it
• The certificate's approved scope, matched against the claim the buyer intends to make
• Current regulatory documents for the destination market

VEMERIX's own entry in the category is the Cyanoacrylate Medical Skin Adhesive in its Wound & Skin range: a single-use adhesive used to aid the closure of small, non-chronic wounds. Market-specific registration and documentation are addressed product-by-product in each supply discussion — the same test the checklist applies to any supplier. VEMERIX works on both sides of this structure — as a legal manufacturer and as a private-label partner — and supports the same document trail it recommends buyers request. The company makes no claim of a new clearance, a portfolio-wide approval, or equivalence to any other manufacturer's adhesive.

"Private-label supply is how this category reaches clinics, and it works well when the documents travel with the product," said Lily (Lianhua) Nan, Founder of Weihai Medison Medical Equipment Co., Ltd. "The checklist is the paperwork we believe should accompany any adhesive — including ours. A buyer who can trace the legal manufacturer behind a brand is a stronger customer for everyone in the chain."

The full report, "Medical Cyanoacrylate Tissue Adhesives (2026): Who Makes Them, How the US, EU and China Class Them, and Where Bulk Supply Comes From," including its sources and scope, is available at https://www.vemerix.com/blog/medical-cyanoacrylate-tissue-adhesive-supplier-landscape-2026. Distribution and OEM/ODM inquiries: [email protected].

About VEMERIX

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform for urology, vascular surgery and perioperative care. Founded in 2003 and headquartered in Yangting, Weihai, Shandong, China, Weihai Medison combines a 2,000-square-meter Class-100K manufacturing base with the Medison Korea Joint Research Institute — a multidisciplinary R&D arm partnered with senior researchers from Seoul National and Yonsei universities and leading Korean research institutes. The VEMERIX portfolio centers on laser energy and surgical consumables, supported by NMPA-registered devices, 50+ patents, ISO 9001 and ISO 13485 quality systems, and senior researchers with 30+ years of cumulative experience in laser, NPWT and biopreparations. VEMERIX products ship to distributors and clinical partners across six continents. More information is available at https://www.vemerix.com.

Company Contact
Ernest Salus Kim
VEMERIX — Public Relations
Weihai Medison Medical Equipment Co., Ltd.
Phone: +86 400-811-7709
Email: [email protected]
Web: https://www.vemerix.com/contact

Media Relations
VEMERIX — Press Inquiries
Phone: +1 415 689 1868
Email: [email protected]

Note to Editors

Lily (Lianhua) Nan is available for interview through the Media Relations contact above. The underlying report was published Sept. 14, 2026 and draws on the FDA 510(k) database (product code MPN, decisions December 2008–September 2025), FDA GUDID device listings, the EU EUDAMED database, China's NMPA UDI database, and UN trade data for HS 3006.10. Counts describe register records as of the report's snapshot, not sales or current market availability; registration is not endorsement, absence from a public snapshot is not evidence of nonconformity, and a labeler without a matched clearance of its own may lawfully relabel under another company's clearance — the 45% figure describes traceability, not compliance.

SOURCE WEIHAI MEDISON (VEMERIX brand)